Donanemab Found to Slow Cognitive, Functional Decline in Early Alzheimer’s

Donanemab Found to Slow Cognitive, Functional Decline in Early Alzheimer’s

282882

Donanemab Found to Slow Cognitive, Functional Decline in Early Alzheimer’s

Donanemab (LY3002813), Eli Lilly’s experimental antibody-based immunotherapy, slowed cognitive and functional decline in patients at the earlier stages of Alzheimer’s disease, according to data from a Phase 2 trial. Findings from this trial, called TRAILBLAZER-ALZ (NCT03367403), also showed donanemab had a favorable safety profile, which was consistent with observations from previous clinical trials. “We are extremely pleased about these positive findings for donanemab as a potential therapy for people living with Alzheimer’s disease, the only…

You must be logged in to read/download the full post.